Pharma and Biotech Contracts in the 2026 Legal Order MasterClass - EU edition

Daniel Gamalski, PhD is an attorney-at-law and doctor of laws with more than 25 years experience in commercial law across the pharmaceutical, biotechnology and healthcare sectors, gained in an international environment. He heads the Life Sciences, Healthcare & Products practice at NGL Legal, advising at every stage of the product lifecycle.

For nearly fifteen years he was part of what is arguably the largest biotechnology undertaking in Central and Eastern Europe. There he built the legal and compliance function from the ground up and served on the operational management team and the risk management committee. He negotiated global licensing, supply and manufacturing agreements of multi-million-euro contribution, led cross-border M&A transactions, coordinated proceedings under the US Biologics Price Competition and Innovation Act (BPCIA), and ran group-level reorganisations. He held legal responsibility for the construction and GMP qualification of large-scale biologics manufacturing facilities and supported FDA and EMA inspections. His research and policy work addresses comparative international contract law associated with pharma operations, supply chains for pharmaceuticals as well as health-system crisis preparedness - at the intersection of law, industrial policy and national security.

He is a graduate in law of the University of Warsaw (commercial law, 2002) and holds a PhD from the University of Gdańsk (commercial law and private international law, 2009), together with a postgraduate qualification in teaching methodology. He has taught for many years in parallel with his in-house practice - commercial law, company law and the law of contract - using his own method built on the analysis of real contractual structures, negotiation simulations and case studies. Member of the Polish Association of Individual Investors, the Allerhand Institute and the InSELT Institute for Strategic Governance.